Pfizer expects to close Medivation buyout in 3Q

Pfizer expects to close Medivation buyout in 3Q


Pfizer expects to complete its $14 billion buyout of cancer drug developer Medivation in the third quarter following the expiration of a regulatory waiting period. The New York drugmaker has agreed to pay $81.50 per Medivation share, which marked a 21 percent premium to San Francisco-based Medivation's closing price when it was announced in August.



from Biotech News